Table 1:
Download
1 / 5

* ongoing lines of GVHD treatment in the monitored timeframe - PowerPoint PPT Presentation


  • 124 Views
  • Uploaded on

Table 1: Clinical characteristics of patients with Acute GVHD.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' * ongoing lines of GVHD treatment in the monitored timeframe' - conley


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Table 1: Clinical characteristics of patients with Acute GVHD

NHL= Non-Hodgkin’s Lymphoma, CLL= Chronic Lymphocytic Leukemia, ALL= Acute Lymphoblastic Leukemia, AML= Acute Myeloblastic Leukemia, MPS= Mucopolysaccaridosis, HLH= Hemophagocytic Lymphohistiocytosis, FLU= Fludarabine, TT= Thiotepa, CY=Cyclophosphamide, TBI= Total Body Irradiation, VP-16= Etoposide, TREO= Treosulfan, BU= Busulfan, SIB= Sibling, URD= Matched Unrelated Donor, UCB= Umbilical Cord Blood, CSA= Cyclosporine A, MTX= Methotrexate, ATG= Anti-Thymocyte Globulin, PDN= Prednisone.

*ongoing lines of GVHD treatment in the monitored timeframe


Table 2: Clinical characteristics of patients with Chronic GVHD

ALL= Acute Lymphoblastic Leukemia, AML= Acute Myeloblastic Leukemia, CML= Chronic Myelocytic Leukemia, THAL= Thalassemia, NHL= Non-Hodgkin’s Lymphoma, TBI= Total Body Irradiation, VP-16= Etoposide, CY= Cyclophosphamide, FLU= Fludarabine, MEL= Melphalan, BU= Busulfan, TREO= Treosulfan, ATG= Anti-Thymocyte Globulin, TT= Thiotepa, URD= Matched Unrelated Donor, FAM= Familiar Donor, SIB= Sibling, HAPLO= Haploidentical, CSA= Cyclosporine A, MTX= Methotrexate, PDN= Prednisone.

*ongoing lines of GVHD treatment in the monitored timeframe


Table 3: Clinical characteristics of patients without GVHD

Patient No. (UPN) and sex

Age at allogeneic HSCT (years)

Diagnosis

Conditioning regimens

Sex disparity

Donor

Prophylaxis/Treatment before GVHD onset

Lines of GVHD treatment*

1/F

11

SAA

CY

yes

SIB

CSA, MTX

0

2/F

5

SAA

BU, CY, MEL

yes

SIB

FK 506

0

3/M

7

ALL

TBI, VP-16, CY

no

SIB

CSA

1

BU, CY, MEL

4/M

13

AML

no

URD

CSA, MTX, ATG

1

BU, CY, MEL

5/M

14

MDS

no

URD

CSA, MTX, ATG

5

BU, CY, MEL

6/M

1

JMML

no

SIB

CSA, MTX, ATG

0

7/ M

9

ALL

TBI, VP-16

yes

URD

ATG

4

8/M

15

ALL

TBI, CY

no

URD

CSA, MTX, ATG

1

BU, CY, MEL

9/F

11

MDS

yes

URD

CSA, MTX, ATG

0

10/M

61

Myeloma

TBI

no

SIB

CY, MTX

1

11/M

45

AML

BU, FLU

no

SIB

CY, MTX

0

12/M

14

ALL

TBI, VP-16

no

SIB

CSA, MTX, ATG

0

13/M

39

ALL

TBI, CY

yes

URD

CY, MTX

1

14/M

68

AML

BU, CY

no

SIB

CSA, MTX

1

15/M

22

ALL

TBI, CY

no

URD

CSA, MTX, ATG

1

16/M

50

ALL

TBI, CY

no

SIB

CSA, MTX,

1

BU, MEL

17/M

59

Myeloma

no

SIB

CSA, MTX,

0

yes

18/F

51

AML

URD

CSA

2

BU, CY, ATG

yes

19/M

55

AML

BU, CY

SIB

CSA, MTX

0

SAA= Severe Aplastic Anaemia, ALL= Acute Lymphoblastic Leukemia,AML= Acute Myeloblastic Leukemia, MDS= Myelodysplastic Syndromes, JMML= Juvenile Myelomonocytic Leukemia, CY=Cyclophosphamide, TBI= Total Body Irradiation, BU= Busulfan, MEL= Melphalan, VP-16= Etoposide, FLU= Fludarabine, ATG= Anti-Thymocyte Globulin, SIB= Sibling, URD= Matched Unrelated Donor, CSA= Cyclosporine A, MTX= Methotrexate.

*ongoing lines of GVHD treatment in the monitored timeframe


ad